Sanofi's Nuvaxovid Covid-19 Vaccine Showed Better Tolerability Than Mnexspike In Head-To-Head Study

TradingKey - The report for Q1 2026 results from Tesla (TSLA) is due on Wednesday, April 22, at the end of the market. After two months of pretty continuous drops, investors are now asking if the TSLA earnings report will provide any insight into the company's margin, growth rate, and overall AI roa

TradingKey - On April 17, Trump declared on social media that the situation in the Strait of Hormuz has concluded, claiming that Iran has agreed to most conditions, including the full reopening of the strait, a commitment to abandon high-enriched uranium stockpiles, and the cessation of support for

TradingKey - Months after withdrawing its previous listing application, AI chipmaker Cerebras Systems has refiled for an IPO, submitting an application to list on the Nasdaq under the ticker symbol "CBRS" on Friday ET. According to Bloomberg, Cerebras had already filed for an IPO confidentially as e

TradingKey - Oklo Inc. (OKLO) is an advanced nuclear technology organization working on fast fission power plants, the ability to produce isotopes, and the recycling of nuclear fuel. Its strategy is to sell electricity generated by its Aurora power plants, using internally manufactured fuel to suppo

TradingKey - On April 16, 2026, OpenAI released GPT-Rosalind, a large language model specifically designed for life sciences research. Initial users include pharmaceutical giant Amgen (AMGN), vaccine manufacturer Moderna (MRNA), and the Allen Institute. Following the announcement, the CRO sector saw a broad decline, with IQVIA Holdings (IQV) falling 3.5% and Charles River Laboratories (CRL) dropping 2.6%. Recursion Pharmaceuticals (RXRX) and Schrodinger (SDGR) both tumbled over 5% at one point.